Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans

Pharmacogenetics

Volumn 6, Issue 4, 1996, Pages 357-360

  Edeki, Timi I ^a   Goldstein, Joyce A ^b   De Morais, Sonia M F ^b   Hajiloo, Leila ^a   Butler, Marcela ^a   Chapdelaine, Perry ^a   Wilkinson, Grant R ^c  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

African American; CYP2C19; Genetic polymorphism; Mephenytoin

Indexed keywords

4' HYDROXYMEPHENYTOIN; CYTOCHROME P450 ISOENZYME; DNA; DRUG METABOLITE; MEPHENYTOIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG METABOLISM; DRUG URINE LEVEL; ENANTIOMER; ETHNIC GROUP; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

EID: 0029775045     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199608000-00009     Document Type: Article

References (28)

1. Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects, Pharmacogenetics 1994: 4, 27-38.
2. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992: 2, 25-31.
3. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, hut not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther 1989: 45, 348-355.
4. Brøsen K, de Morais SMF, Meyer U, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995: 5, 312-317.
5. de Morals SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K., Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994a: 269, 15419-15422.
6. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer US, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharm 1994b: 46, 594-598.
7. de Morais SMF, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995: 58, 404-411.
8. Doshi BS, Kulkarni KD, Chauhan BL, Wilkinson GR. Frequency of impaired mephenytoin 4′-hydroxylase in an Indian population. Br J Clin Pharmacol 1990: 30, 779-780.
9. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker HM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenyloin 4′-hydroxylase in humans. Biochemistry 1994: 33, 1743-1752.
10. Greenblatt DJ, Allen MD, Harmatz JS, Shader RI, Diazepam disposition determinants. Clin Pharmacol Ther 1980: 27, 301-312.
11. Inaba T, Jorge LF, Arias TD. Mephenytoin hydroxylation in the Cuna Indians of Panama. Br J Clin Pharmacol 1988: 25, 75-79.
12. Iyun AO, Tucker GT, Woods HF, Lennard MS. The 4-hydroxylation of (S)-mephenytoin in Nigerians: a population study. Br J Clin Pharmacol 1990: 30, 312P.
13. Küpfer A, Branch RA. Stereoselective mephobarbital hydroxylation cosegrates with mephenytoin hydroxylation. Clin Pharmacol Ther 1985: 38, 414-418.
14. Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984: 26, 753-759.
15. Masmirembwa C, Bertilsson L, Johnasson I, Hasler JA, Ingleman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19 in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995: 57, 656-661.
16. May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase. a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994: 55, 492-500.
17. Pollock BG, Perel JM, Kirshner M, Altieri LP, Yeager AL, Reynolds III CF. S-mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol 1991: 40, 609-611.
18. Reed TE. Caucasian genes in American Negroes. Science 1969: 165, 762-768.
19. Walle T, Walle UK, Cowart TD, Conradi EC. Pathway-selective sex differences in the metabolic clearance of propranolol in humans subjects. Clin Pharmacol Ther 1989: 46, 257-263.
20. Ward SA, Goto F, Nakamura K, Jacqz E, Wilkinson GR, Branch RA. S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families. Clin Pharmacol Ther 1987: 42, 96-99.
21. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin Pharmacol Ther 1989: 45, 72-79.
22. Ward SA, Helsby NA, Skjelbo E, Brøosen K, Gram LF, Breckenridge, AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism-a panel study. Br J Clin Pharmacol 1991: 31, 689-692.
23. Wedlund PJ, Aslanian SW, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians; frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984: 36, 773-780.
24. Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA. Pharmacogenetic association between the formation of 4-hydroxy-mephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Disp 1987: 15, 277-279.
25. Weerasuriya K, Jayakody RL,Smith CAD, Wolf CR, Tucker GT, Lennard MS. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Br J Clin Pharmacol 1994: 38, 466-470.
26. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989: 43, 53-76.
27. Wrighton SA, Stevens JC, Becker BW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993: 306, 240-245.
28. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ. Limitation to the use of urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1992: 31, 350-352. (1991)